Munoz-Barrera, L.Perez-Sanchez, C.Contreras, A. EscuderoAguirre-Zamorano, M. A.Gutierrez, J. CalvoCastro, R. OrtegaRomero-Gomez, M.Sanchez-Pareja, I.Abalos-Aguilera, M. C.Puerto, N. BarbarrojaVenegas, J. J. PerezRuiz-Montesinos, D.Rodriguez-Escalera, C.Romero-Barco, C. M.Mena-Vazquez, N.Fernandez-Nebro, A.Uceda, J.Marenco, J. L.Estevez, E. CollantesLopez-Pedreraon, C.2023-05-032023-05-032022-06-01Muñoz-Barrera L, Perez-Sanchez C, Contreras AE, Aguirre-Zamorano MÁ, Gutierrez JC, Castro RO, et al. POS0440 THE ANALYSIS OF THE INFLAMMATORY PROTEOME IN RHEUMATOID ARTHRITIS IDENTIFIES COMMON SIGNATURES ASSOCIATED WITH THE CLINICAL RESPONSE TO DMARDs AND TNFI THERAPIES. Annals Of The Rheumatic Diseases [Internet]. 23 de mayo de 2022;81(Suppl 1):475.1-4750003-4967http://hdl.handle.net/10668/20117Background: The clinical outcome of the most common therapeutic options of rheumatoid arthritis (RA) patients, such as conventional disease-modifying antirheumatic drugs (DMARDs) and TNF inhibitors (TNFi) is still unpredictable, since a high percentage of patients do not response to the therapy. Innovative analyses combining high-throughput technologies and thorough clinical assessments are needed to gain insight about the management of this prevalent autoimmune disorder.enConference outputopen access10.1136/annrheumdis-2022-eular.44661468-2060https://ard.bmj.com/content/annrheumdis/81/Suppl_1/475.1.full.pdf850279001376